Nonalcoholic fatty liver disease and hepatic cirrhosis: Comparison with viral hepatitis-associated steatosis

World J Gastroenterol. 2015 Dec 14;21(46):12989-95. doi: 10.3748/wjg.v21.i46.12989.

Abstract

Nonalcoholic fatty liver disease (NAFLD) including nonalcoholic steatohepatitis (NASH) is globally increasing and has become a world-wide health problem. Chronic infection with hepatitis B virus or hepatitis C virus (HCV) is associated with hepatic steatosis. Viral hepatitis-associated hepatic steatosis is often caused by metabolic syndrome including obesity, type 2 diabetes mellitus and/or dyslipidemia. It has been reported that HCV genotype 3 exerts direct metabolic effects that lead to hepatic steatosis. In this review, the differences between NAFLD/NASH and viral hepatitis-associated steatosis are discussed.

Keywords: Hepatitis B virus; Hepatitis C virus; Hepatocellular carcinoma; Non-alcoholic fatty liver disease; Non-alcoholic steatohepatitis.

Publication types

  • Editorial
  • Review

MeSH terms

  • Animals
  • Antiviral Agents / therapeutic use
  • Biomarkers / blood
  • Fatty Liver / diagnosis
  • Fatty Liver / drug therapy
  • Fatty Liver / epidemiology*
  • Fatty Liver / virology
  • Hepatitis B, Chronic / diagnosis
  • Hepatitis B, Chronic / drug therapy
  • Hepatitis B, Chronic / epidemiology*
  • Hepatitis B, Chronic / virology
  • Hepatitis C, Chronic / diagnosis
  • Hepatitis C, Chronic / drug therapy
  • Hepatitis C, Chronic / epidemiology*
  • Hepatitis C, Chronic / virology
  • Humans
  • Liver Cirrhosis / diagnosis
  • Liver Cirrhosis / drug therapy
  • Liver Cirrhosis / epidemiology*
  • Liver Cirrhosis / virology
  • Non-alcoholic Fatty Liver Disease / diagnosis
  • Non-alcoholic Fatty Liver Disease / epidemiology*
  • Predictive Value of Tests
  • Prevalence
  • Prognosis
  • Risk Factors

Substances

  • Antiviral Agents
  • Biomarkers